Lifecare’s partner Digital Diagnostics AG seeks additional approval in Germany for corona virus rapid test …(Note: This headline has been truncated)

Lifecare’s partner Digital Diagnostics AG seeks additional approval in Germany
for corona virus rapid test – plan for scaling capacities with production
partners in USA and Europe and aim to bring test to the market in millions. 

The Norwegian listed company Lifecare AS (LIFE-ME) has a 25% ownership in
Digital Diagnostics AG which has developed an accurate and reliable rapid test
able to detect corona virus from the time of infection, contrary to other tests
on the market that can only detect the antibodies 5-7 days after the infection.
The test is independent of lab analysis, providing test result within minutes at
the point-of-care. 

Digital Diagnostics announced June 12th, 2020, that the company has applied to
the German Federal Institute for Drugs and Medical Devices (BfArM) for approval
of the Digid CantisenseTM SARS-CoV-2 test for Germany. This application comes in
addition to the previous application to the US FDA, announced June 2de, 2020. 

Digital Diagnostics expect approval from BfArM and FDA in the next few weeks,
where after the goal is to bring the tests to the market in millions. In the
short-term Digital Diagnostics are further scaling its capasities with
production partners in the USA and Europe.   

https://app.handelsblatt.com/technik/forschung-medizin/pandemie-corona-nachweis-
in-fuenf-minuten-neue-generation-von-schnelltests-draengt-auf-den-markt/25905060
.html?ticket=ST-3806779-6C6zKjUKJhghdkEmaDdF-ap3


For additional background information, we refer to: 
https://newsweb.oslobors.no/message/506937


Press contact Lifecare
Christian Saure
Chairman of the Board
christian@sternacap.no
+47 909 33 148